Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...

Antiepileptic Drugs: GABAergic Pathway Potentiators

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...

CNS Depressants: Barbiturates and Benzodiazepines

CNS Depressants: Barbiturates and Benzodiazepines

CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...

Sedatives and Hypnotics Drugs: Benzodiazepines

Sedatives and Hypnotics Drugs: Benzodiazepines

Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Biomarker-driven therapeutic strategies in advanced gastric cancer: a case series of curative responses.

Journal of gastrointestinal oncology·2025

Same author

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors.

Journal for immunotherapy of cancer·2024

Same author

Re-evaluating the role of pelvic radiation in the age of modern precision medicine and systemic therapy.

World journal of clinical oncology·2024

Same author

Neoadjuvant Chemotherapy With/Without Radiotherapy for Locally Advanced Rectal Cancer: A Nationwide Retrospective Cohort Study.

Anticancer research·2023

Same author

Clinical Features and Outcomes of Primary Breast Diffuse Large B-Cell Lymphoma: A Matched-Pair Study.

Clinical Medicine Insights. Oncology·2023

Same author

Pelvic Neoadjuvant Radiotherapy for Stage M1a Rectal Adenocarcinoma Patients Treated With Systemic Therapy Followed by Proctectomy and Metastasectomy: A Nationwide Retrospective Cohort Study.

Anticancer research·2023

Search research articles

Related Experiment Video

Updated: Jun 10, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Pancytopenia associated with clonazepam.

Marnelli A Bautista-Quach¹, Yu-Min Liao, Chung-Tsen Hsueh

¹Department of Pathology and Laboratory Medicine, Loma Linda University Medical Center, CA 92354, USA.

Journal of Hematology & Oncology

|July 16, 2010

Summary

Clonazepam use in a patient with end-stage renal disease led to pancytopenia, a severe drop in blood cell counts. Discontinuation of clonazepam resulted in recovery, highlighting the need for blood count monitoring in patients on this medication.

More Related Videos

Pentylenetetrazole-Induced Kindling Mouse Model

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Related Experiment Videos

Last Updated: Jun 10, 2026

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

Pentylenetetrazole-Induced Kindling Mouse Model

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Area of Science:

Hematology
Pharmacology

Background:

A 48-year-old female with end-stage renal disease and chronic anemia on hemodialysis was prescribed clonazepam for myoclonus.
Two weeks after initiating clonazepam, she was hospitalized with neutropenic fever, thrombocytopenia, and worsening anemia.

Observation:

Bone marrow examination revealed markedly hypocellular marrow (10-20% cellularity).
The patient's symptoms of thrombocytopenia and neutropenia gradually improved within 1-2 weeks after discontinuing clonazepam.

Findings:

This case represents the first reported instance of pancytopenia associated with clonazepam use.
The findings suggest a potential causal link between clonazepam and the development of pancytopenia in susceptible individuals.

Implications:

Patients prescribed clonazepam, especially those with pre-existing hematological conditions or on hemodialysis, should undergo regular complete blood count monitoring.
Early detection and discontinuation of clonazepam may prevent severe hematological complications like pancytopenia and thrombocytopenia.